About half of drinkers on GLP-1s say they imbibed less

by Alvin Powell, Harvard University

edited by Sadie Harley, reviewed by Andrew Zinin

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add to Preferred Sources

Nearly half of drinkers who take GLP-1 medications have reported declines in consumption, with the effect higher among those at risk of unhealthy alcohol use, a new Harvard study shows. The work, published in the journal JAMA Psychiatry, explores an unexpected side effect of GLP-1s used to treat diabetes and obesity.

The drugs' effectiveness, particularly for weight loss, has caused them to skyrocket in popularity and, as use spread, anecdotal evidence emerged about improvements in heart health and mental well-being, and reduced cravings for alcohol among patients.

Researchers from Harvard Medical School and McLean Hospital worked on the survey with collaborators from Brown, Duke and Brandeis universities and Boston-based RAND Corporation.

The study grew out of work by senior author Haiden Huskamp, HMS' Henry J. Kaiser professor of health care policy, and co-author Alisa Busch, HMS professor of psychiatry at McLean Hospital and associate professor of health care policy at HMS, on the underuse of medications to treat alcohol use disorder.

Anti-abuse medications have existed for decades—disulfiram, the oldest, has been around since the 1940s.

Just 3% to 5% of those with a past alcohol abuse disorder reported using the drugs in a recent national survey, and only 10% of those seeking treatment have received the approved drugs.

"The national surveys show that far and away most people with alcohol use disorder receive no treatment, period," Busch said. "We have this evidence-based treatment that's efficacious, so what are the patient characteristics, the clinician characteristics associated with being prescribed or not prescribed these medications?"

Busch, Huskamp and their team took notice as accounts emerged about reduced cravings to drink among patients on GLP-1s. As reports multiplied and their effect on individuals became clearer, the two wanted to better understand the phenomenon on a population level.

"We wanted to really understand patient perception of this issue, and a large share of people taking GLP-1s are saying they're drinking less," Huskamp said.

The current study surveyed RAND's American Life Panel, a group of adults from across the nation who are issued internet-connected devices to complete surveys, in March and April 2026. Of 2,009 who completed the initial survey, 368 reported current or past use of GLP-1s, and 242 said they were drinkers when they began taking a GLP-1.

Of those reporting drinking while on GLP-1s, 44.2%, or 106, said they consumed less. Most of the rest reported no change, with three saying they drank more.

The survey also asked a single screening question for unhealthy alcohol use: whether at any single time in the previous year the respondent had imbibed enough to be considered heavy drinking—four drinks for women, five for men, according to the National Institutes of Health.

The authors defined that group as GLP-1 users at risk for unhealthy drinking. They found 54.1% of that population reported drinking less, 40.2% said there was no change, and 5.7%—three individuals—were drinking more.

"Because all of the evidence had been anecdotal when we started this study, it was hard to know what to expect," Huskamp said. "But finding that about half of GLP-1 users who drink reported reductions in their alcohol use after starting the medication is pretty striking."

Huskamp and Busch cautioned against leaping to the conclusion that GLP-1s should join other medications approved to treat alcohol use disorder because the study screened for potentially unhealthy use, not alcohol use disorder—a clinical diagnosis for those whose drinking causes significant disruption to daily life and health.

Also missing from the analysis was evidence of the magnitude of the decline in drinking.

"We weren't testing GLP-1s for efficacy in reducing alcohol use. We'd need a randomized controlled trial for that," Busch said. "We were trying to understand, in a population at higher risk for harmful drinking, is there a difference in their experience of drinking alcohol compared to individuals who screen negative?"

Another significant finding was that the awareness about reduced alcohol consumption among those taking GLP-1s was low. Just 10% of all those surveyed said they had heard that GLP-1s might lower drinking.

Those deeper questions about the potential utility of GLP-1s to reduce alcohol consumption await the results of clinical trials—some of which have already begun—designed to answer those questions.

"The evidence isn't there, but it will be very interesting to watch over the next couple of years," Huskamp said. "There are trials underway. I don't expect it to take too long before more evidence starts coming through."

Publication details

Lori Uscher-Pines et al., Patient-Reported Changes in Alcohol Use Following Glucagon-Like Peptide-1 Receptor Agonist Initiation, JAMA Psychiatry (2026). DOI: 10.1001/jamapsychiatry.2026.3242

Journal information: JAMA Psychiatry

Clinical categories

Clinical pharmacologyPsychology & Mental healthPsychiatryCommon illnesses & Prevention Provided by Harvard University Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

This story is published courtesy of the Harvard Gazette, Harvard University's official newspaper. For additional university news, visit Harvard.edu.

Citation: About half of drinkers on GLP-1s say they imbibed less (2026, November 3) retrieved 3 November 2026 from https://medicalxpress.com/news/2026-11-drinkers-glp-1s-imbibed.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.